Open Access
| Issue |
BIO Web Conf.
Volume 202, 2025
International Conference of Bioscience, Biodiversity, and Biotechnology (ICB3 2025)
|
|
|---|---|---|
| Article Number | 03005 | |
| Number of page(s) | 9 | |
| Section | Biotechnology, Bioinformatics, and Biosciences | |
| DOI | https://doi.org/10.1051/bioconf/202520203005 | |
| Published online | 10 December 2025 | |
- G. Hindricks, T. Potpara, N. Dagres, et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 42, 373–498 (2021). https://doi.org/10.1093/eurheartj/ehaa612 [Google Scholar]
- V.N. Larina, O.Sh. Oinotkinova, A.P. Mayorova, An integrated approach to the management of a multimorbid patient with atrial fibrillation from the standpoint of modern recommendations. Rational Pharmacother. Cardiol. 17, 484–491 (2021). https://doi.org/10.20996/1819-6446-2021-06-05 [Google Scholar]
- H. Watanabe, T. Watanabe, S. Sasaki, et al., Close bidirectional relationship between chronic kidney disease and atrial fibrillation. Am. Heart J. 158, 629–636 (2009). https://doi.org/10.1016/j.ahj.2009.06.031 [Google Scholar]
- A. Gomez-Outes, J. Lagunar-Ruiz, A.-I. Terleira-Fernandez, et al., Causes of death in anticoagulated patients with atrial fibrillation. J. Am. Coll. Cardiol. 68, 2508–2521 (2016). https://doi.org/10.1016/j.jacc.2016.09.944 [Google Scholar]
- A.N. Turov, S.V. Panfilov, O.V. Chiglintseva, Efficacy, safety and adherence when using new anticoagulants in patients with atrial fibrillation over 75 years of age. Rational Pharmacother. Cardiol. 16, 10–18 (2020). https://doi.org/10.20996/1819-6446-2020-20-07 [Google Scholar]
- A. Bracey, W. Shatila, J. Wilson, Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. Ther. Adv. Cardiovasc. Dis. 12, 361–380 (2018). https://doi.org/10.1177/1753944718801554 [Google Scholar]
- J. Beyer-Westendorf, S. Marten, Ch. Naue, et al., Rates, management and outcome of bleeding complications during edoxaban therapy in daily care – results from the DRESDEN NOAC REGISTRY. Thromb. Res. 190, 91–98 (2020). https://doi.org/10.1016/j.thromres.2020.03.021 [Google Scholar]
- X. Feng, U. Sambamoorthi, K. Innes, et al., Predictors of major bleeding among working-age adults with atrial fibrillation. Cardiovasc. Drugs Ther. 32, 591–600 (2018). https://doi.org/10.1007/s10557-018-6825-7 [Google Scholar]
- T.J. Milling Jr, J. Frontera, Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding. Am. J. Manag. Care 23, S67–S80 (2017). [Google Scholar]
- S. Ono, M. Ishikawa, K. Matsuda, et al., Clinical impact of the perioperative management of oral anticoagulants in bleeding after colonic endoscopic mucosal resection. BMC Gastroenterol. 19, 206 (2019). https://doi.org/10.1186/s12876-019-1124-8 [Google Scholar]
- M.R. Patel, K.W. Mahaffey, J. Garg, et al.; ROCKET AF Investigators, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883–891 (2011). https://doi.org/10.1056/NEJMoa1009638 [Google Scholar]
- O. Hanon, J.S. Vidal, G. Pisica-Donose, et al., Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart 107, 1376–1382 (2021). https://doi.org/10.1136/heartjnl-2020-3179237 [Google Scholar]
- E.S. Kropacheva, Practical aspects of therapy with new oral anticoagulants in patients with impaired renal function. Kardiologiia 2, 78–83 (2014). https://doi.org/10.18565/cardio.2014.4.78-83 [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.